Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5414/NP300900 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chordoid Meningioma: The Rarest Subtype of Grade II Meningioma.
Cureus
November 2024
Pathology and Laboratory Medicine, Palmetto General Hospital, Hialeah, USA.
Chordoid meningioma, a rare WHO grade II tumor, is known for its aggressive behavior and high recurrence rate. We report a case of a 44-year-old woman with progressive left-sided weakness, where imaging revealed a 3.0 cm lesion in the right sphenoidal wing with significant midline shift and edema.
View Article and Find Full Text PDFClinical and Imaging Features of Head and Neck Metastasis of High-Grade Glioma: A Single-Center Case Series.
AJNR Am J Neuroradiol
January 2025
Departments of Neuroradiology and Imaging Physics (D.S.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
High-grade gliomas are the most frequent primary brain tumors, yet extraneural metastasis is exceedingly rare. This is in part secondary to the relatively poor survival of these patients and likely the shielding effect of the blood-brain barrier. Given the rarity of extraneural metastasis, the pathophysiology and imaging appearance of extraneural metastasis is under-reported and poorly understood.
View Article and Find Full Text PDFMultiple Central Nervous System Cryptococcomas Masquerading as Lymphoma.
Neurohospitalist
December 2024
Department of Neurology, TriStar Centennial Medical Center, Nashville, TN, USA.
Cryptococcal meningitis is a leading cause of morbidity and mortality in patients infected with human immunodeficiency virus. In over 90% of cases, it occurs at CD4 T lymphocyte (CD4) cell counts of less than 100 cells/mm. Cryptococcomas are rare granulomatous lesions that can occur in disseminated central nervous system cryptococcal infection, primarily in immunocompetent hosts.
View Article and Find Full Text PDFDeep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer's, vascular and Lewy body dementias.
Brain
December 2024
Neuroimage Analytics Laboratory and Biggs Institute Neuroimaging Core, Glenn Biggs Institute for Neurodegenerative Disorders, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.
Concurrent neurodegenerative and vascular pathologies pose a diagnostic challenge in the clinical setting, with histopathology remaining the definitive modality for dementia-type diagnosis. To address this clinical challenge, we introduce a neuropathology-based, data-driven, multi-label deep learning framework to identify and quantify in-vivo biomarkers for Alzheimer's disease (AD), vascular dementia (VD), and Lewy body dementia (LBD) using antemortem T1-weighted MRI scans of 423 demented and 361 control participants from NACC and ADNI datasets. Based on the best-performing deep learning model, explainable heatmaps are extracted to visualize disease patterns, and the novel Deep Signature of Pathology Atrophy REcognition (DeepSPARE) indices are developed, where a higher DeepSPARE score indicates more brain alterations associated with that specific pathology.
View Article and Find Full Text PDFSensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study.
Lancet Neurol
December 2024
Amprion, San Diego, CA, USA. Electronic address:
Article Synopsis
- A novel α-synuclein seed amplification assay (synSAA) was developed to differentiate misfolded α-synuclein seeds linked to multiple system atrophy (MSA) and Parkinson's disease (PD).
- The study analyzed cerebrospinal fluid (CSF) and brain samples from various clinical cohorts across multiple medical centers to assess the assay's diagnostic accuracy.
- Findings showed that brain samples with Lewy bodies were positive for synSAA, indicating potential for the assay in distinguishing between MSA and PD in diagnostic settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!